Oncimmune Holdings plc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Oncimmune Holdings plc - overview
Established
2006
Location
Nottingham, -, UK
Primary Industry
Biotechnology
About
Based in Nottingham, UK, and founded in 2006 by John Robertson, Oncimmune Holdings Plc operates as a biotechnology company that primarily focuses on advancing the early detection of cancer. In May 2023, Freenome Holdings, Inc. acquired Oncimmune Limited from Oncimmune Holdings plc for GBP 13 million. Oncimmune Holdings PLC is a cancer diagnosis company that is committed to advancing early cancer detection through its proprietary autoantibody testing technologies, which are based on biological technology.
The company is active in the development, manufacturing, and commercialization of personalized immunodiagnostics for cancer screening, detection, and treatment. Early CDT Lung and ImmunoINSIGHTS are two of its business segments.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Diagnostic, Medical & Imaging Laboratories, Oncology/Cancer Treatment, Diagnostic Equipment
Website
www.oncimmune.com
Verticals
HealthTech, Manufacturing
Total Amount Raised
Subscriber access only
Oncimmune Holdings plc - timeline of key events
Oncimmune Holdings plc - financials
| Fiscal Year Ended | May 31, 2016 | May 31, 2017 | May 31, 2018 | May 31, 2019 | May 31, 2020 | May 31, 2021 | Aug 31, 2022 | Aug 31, 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 430,000 | 215,000 | 240,000 | 171,000 | 509,000 | - | - | - |
| % Revenue Growth (YoY) | - | (50.0%) | 11.6% | (28.8%) | 197.7% | - | - | - |
| EBITDA (USD) | (5,636,000) | (5,182,000) | (6,194,000) | (8,350,000) | (8,768,000) | - | - | - |
| Operating Income (USD) | (5,714,000) | (5,273,000) | (6,374,000) | (8,589,000) | (9,268,000) | - | - | - |
| Operating Margin | (1328.8%) | (2452.6%) | (2655.8%) | (5022.8%) | (1820.8%) | - | - | - |
| % EBITDA Margin | (1310.7%) | (2410.2%) | (2580.8%) | (4883.0%) | (1722.6%) | - | - | - |
| NET Income (USD) | (8,442,000) | (5,023,000) | (6,342,000) | (8,012,000) | (8,459,000) | - | - | - |
| % Net Margin | (1963.3%) | (2336.3%) | (2642.5%) | (4685.4%) | (1661.9%) | - | - | - |
Oncimmune Holdings plc - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.